Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Low Drug Levels in Lymphatic Tissue May Underlie Low HIV Viral Load

HIV continues to replicate in the lymph nodes of people taking antiretroviral therapy (ART) that suppresses viral load in peripheral blood, according to a small study in the January 27 early online edition of Proceedings of the National Academy of Sciences. Several commonly used antiretroviral drugs reached lower concentrations in lymphatic tissue compared with blood, allowing ongoing virus production that may contribute to increased inflammation and immune activation in people with apparently well-controlled HIV.

alt

Read more:

Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.alt

Read more:

Short Antiretroviral Therapy Beneficial during Primary HIV Infection

A short course of combination antiretroviral therapy (ART) started during primary HIV infection is associated with CD4 T-cell gains and viral load reductions after treatment is stopped, according to a meta-analysis published in the December 6 edition of PLoS ONE.

alt

Read more:

Dolutegravir for HIV and Sofosbuvir for Hepatitis C Approved in Europe

The European Commission this week approved 2 important new drugs, ViiV Healthcare's HIV integrase inhibitor dolutegravir (brand name Tivicay) and Gilead Science's nucleotide hepatitis C virus polymerase inhibitor sofosbuvir (Sovaldi).

alt

Read more:

Happy New Year from HIVandHepatitis.com

alt

Ribonucleoside Analogs May Be Potential New Class of HIV Drug

A set of compounds known as ribonucleoside analogs -- related to the nucleoside/nucleotide reverse transcriptase inhibitors that currently form the backbone of combination antiretroviral therapy -- demonstrated activity against HIV in laboratory studies, halting viral replication by interrupting HIV DNA production or causing lethal mutations, according to a report in the January 2014 Journal of Virology.

alt

Read more:

HIVandHepatitis.com Complete 2013 Conference Coverage

HIVandHepatitis.com 2013 conference and meeting coverage.

Full conference listing

12/30/13

alt